Abstract: Disclosed are methods relating to amplification and expression of a nucleic acid sequence encoding a polypeptide of interest in recombinant cells, and cell lines and polypeptides produced from such methods. The methods disclosed herein permit the amplification of cell lines that express a polypeptide of interest in a relatively short period of time through the use of a bioreactor.
Abstract: The present invention provides novel human sequence antibodies against human CTLA-4 and methods of treating human diseases, infections and other conditions using these antibodies.
Type:
Grant
Filed:
August 4, 2011
Date of Patent:
November 27, 2012
Assignee:
Medarex, Inc.
Inventors:
Alan J. Korman, Edward L. Halk, Nils Lonberg, Yashwant M. Deo, Tibor P. Keler
Abstract: Antibodies that specifically bind to toxins of C. difficile, antigen binding portions thereof, and methods of making and using the antibodies and antigen binding portions thereof are provided herein.
Type:
Application
Filed:
June 7, 2012
Publication date:
November 15, 2012
Applicants:
MEDAREX, INC., UNIVERSITY OF MASSACHUSETTS
Inventors:
Donna AMBROSINO, Gregory J. BABCOCK, Teresa BROERING, Robert GRAZIANO, Hector Javier HERNANDEZ, Israel LOWY, Robert MANDELL, Deborah MOLRINE, William D. THOMAS, JR., Hui-Fen ZHANG
Abstract: The invention pertains to anti-CD30 antibodies that lack fucosyl and xylosyl residues. The antibodies of the invention exhibit increased antibody-dependent cellular cytotoxicity (ADCC) activity, including the ability to lyse CD30-expressing cell lines that are not lysed by the fucosylated and xylosylated form of the antibodies. The invention also provides host cells that express the anti-CD30 antibodies that lack fucosyl and xylosyl residues, wherein the host cells are deficient for a fucosyltransferase and a xylosyltransferase. Methods of using the antibodies to inhibit the grown of CD30+ cells, such as tumor cells, are also provided.
Type:
Application
Filed:
April 18, 2012
Publication date:
November 1, 2012
Applicants:
MEDAREX, INC., BIOLEX THERAPEUTICS, INC.
Inventors:
Amelia Nancy BLACK, David B. PASSMORE, Mohan SRINIVASAN, Lynn F. DICKEY, Kevin M. COX, Charles G. PEELE, Ming-Bo WANG
Abstract: Antibodies that interact with interleukin-1 receptor type 1 (IL-1R1) are described. Methods of treating IL-1 mediated diseases by administering a pharmaceutically effective amount of antibodies to IL-1R1 are described. Methods of detecting the amount of IL-1R1 in a sample using antibodies to IL-1R1 are described.
Type:
Application
Filed:
April 18, 2012
Publication date:
October 25, 2012
Applicants:
Medarex, Inc., Amgen Inc.
Inventors:
Brian Varnum, Chris Vezina, Alison Witte, Xueming Qian, Francis Hall Martin, Haichun Huang, Gary Elliott
Abstract: This invention provides antibodies that interact with or bind to human interferon-gamma (IFN-?) and methods for treating IFN-? mediated diseases by administering a pharmaceutically effective amount of antibodies to IFN-?. Methods of detecting the amount of IFN-? in a sample using antibodies to IFN-? are also provided.
Type:
Application
Filed:
May 21, 2012
Publication date:
October 25, 2012
Applicants:
MEDAREX, INC., AMGEN INC.
Inventors:
Andrew A. Welcher, Hilary T. Chute, Yue-Sheng Luke Li, Haichun Huang
Abstract: The present invention relates to a method of enhancing the anti-tumor response in a mammal. More particularly, the invention is concerned with combinations comprising a cytokine-secreting cell and an anti-PD-1 antibody, and methods of administering the combination for enhanced immune response to tumor cells in a patient with a cancer.
Type:
Grant
Filed:
July 19, 2010
Date of Patent:
October 16, 2012
Assignees:
BioSante Pharmaceuticals, Inc., Medarex, Inc.
Abstract: The invention pertains to anti-CD30 antibodies that lack fucosyl residues. The antibodies of the invention exhibit increased antibody-dependent cellular cytotoxicity (ADCC) activity, including the ability to lyse CD30-expressing cell lines that are not lysed by the fucosylated form of the antibodies. The invention also provides host cells that express the anti-CD30 antibodies that lack fucosyl residues, wherein the host cells are deficient for a fucosyl transferase. Methods of using the antibodies to inhibit the growth of CD30+ cells, such as tumor cells, are also provided.
Type:
Application
Filed:
May 2, 2012
Publication date:
October 4, 2012
Applicant:
MEDAREX, INC.
Inventors:
Josephine M. CARDARELLI, Amelia Nancy BLACK
Abstract: The present invention provides isolated monoclonal antibodies, particularly human antibodies, that bind to IP-10 with high affinity, inhibit the binding of IP-10 to its receptor, inhibit IP-10-induced calcium flux and inhibit IP-10-induced cell migration. Nucleic acid molecules encoding the antibodies of the invention, expression vectors, host cells and methods for expressing the antibodies of the invention are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the invention are also provided. The invention also provides methods for inhibiting IP-10 activity using the antibodies of the invention, including methods for treating various inflammatory and autoimmune diseases.
Type:
Application
Filed:
May 23, 2012
Publication date:
September 13, 2012
Applicant:
MEDAREX, INC.
Inventors:
Shrikant DESHPANDE, Haichun HUANG, Mohan SRINIVASAN, Josephine M. CARDARELLI, Changyu WANG, David PASSMORE, Vangipuram RANGAN, Thomas E. LANE, Hans S. KEIRSTEAD, Michael T. LIU
Abstract: The present invention provides isolated monoclonal antibodies that bind to CTLA-4 and that are capable of increasing the response of T cells to antigenic stimulation in vivo yet the antibodies do not substantially block the binding of CTLA-4 to B7 ligands (e.g., B7-1 and B7-2) in vitro. Thus, the antibodies of the invention demonstrate that is it possible to separate the immunostimulatory function of anti-CTLA-4 antibodies from their ability to block the binding of B7 ligands. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the invention are also provided. The invention also provides methods for increasing the response of T cells to antigenic stimulation using the antibodies of the invention, including methods for treating cancer using the antibodies of the invention.
Type:
Grant
Filed:
February 4, 2009
Date of Patent:
September 11, 2012
Assignee:
Medarex, Inc.
Inventors:
Alan Korman, Edward L. Halk, Changyu Wang, Kent B. Thudium, Lan Yang, Kristopher Toy
Abstract: The present invention provides isolated monoclonal antibodies, particularly human antibodies, that bind to IP-10 with high affinity, inhibit the binding of IP-10 to its receptor, inhibit IP-10-induced calcium flux and inhibit IP-10-induced cell migration. Nucleic acid molecules encoding the antibodies of the invention, expression vectors, host cells and methods for expressing the antibodies of the invention are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the invention are also provided. The invention also provides methods for inhibiting IP-10 activity using the antibodies of the invention, including methods for treating various inflammatory and autoimmune diseases.
Type:
Grant
Filed:
May 27, 2009
Date of Patent:
September 4, 2012
Assignee:
Medarex, Inc.
Inventors:
Shrikant Deshpande, Haichun Huang, Mohan Srinivasan, Josephine M. Cardarelli, Changyu Wang, David B. Passmore, Vangipuram Rangan, Thomas E. Lane, Hans S. Keirstead, Michael T. Liu
Abstract: Antibodies that specifically bind to toxins of C. difficile, antigen binding portions thereof, and methods of making and using the antibodies and antigen binding portions thereof are provided herein.
Type:
Grant
Filed:
July 31, 2009
Date of Patent:
September 4, 2012
Assignees:
University of Massachusetts, Medarex, Inc.
Inventors:
Donna M. Ambrosino, Gregory J. Babcock, Teresa Broering, Robert Graziano, Hector Javier Hernandez, Israel Lowy, Robert Mandell, Deborah Molrine, William D. Thomas, Jr., Hui-Fen Zhang
Abstract: The present invention provides isolated monoclonal antibodies, particularly human monoclonal antibodies, that specifically bind to PTK7 with high affinity. Nucleic acid molecules encoding the antibodies of the invention, expression vectors, host cells and methods for expressing the antibodies of the invention are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the invention are also provided. The invention also provides methods for detecting PTK7, as well as methods for treating various diseases, including cancer and infectious diseases, using anti-PTK7 antibodies.
Type:
Application
Filed:
May 10, 2012
Publication date:
August 30, 2012
Applicant:
MEDAREX, INC.
Inventors:
Jonathan Alexander TERRETT, Li-Sheng LU, Chin PAN
Abstract: The present disclosure provides isolated monoclonal antibodies, particularly human monoclonal antibodies that specifically bind to BTLA with high affinity. Nucleic acid molecules encoding the antibodies of the disclosure, expression vectors, host cells and methods for expressing the antibodies of the disclosure are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the disclosure are also provided. The disclosure also provides methods for detecting BTLA, as well as methods for treating various diseases, including cancer and infectious diseases, using anti-BTLA antibodies.
Type:
Grant
Filed:
November 15, 2007
Date of Patent:
August 21, 2012
Assignee:
Medarex, Inc.
Inventors:
Alan Korman, Mark Selby, Kent B. Thuduim, Edward Halk, Mohan Srinivasan, David B. Passmore
Abstract: The present invention provides isolated monoclonal antibodies, particularly human monoclonal antibodies, that specifically bind to PTK7 with high affinity. Nucleic acid molecules encoding the antibodies of the invention, expression vectors, host cells and methods for expressing the antibodies of the invention are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the invention are also provided. The invention also provides methods for detecting PTK7, as well as methods for treating various diseases, including cancer and infectious diseases, using anti-PTK7 antibodies.
Type:
Application
Filed:
April 9, 2012
Publication date:
August 16, 2012
Applicant:
MEDAREX, INC.
Inventors:
Jonathan Alexander TERRETT, Li-Sheng LU, Chin PAN
Abstract: Antibodies that interact with interleukin-1 receptor type 1 (IL-1R1) are described. Methods of treating IL-1 mediated diseases by administering a pharmaceutically effective amount of antibodies to IL-1R1 are described. Methods of detecting the amount of IL-1R1 in a sample using antibodies to IL-1R1 are described.
Type:
Grant
Filed:
September 15, 2008
Date of Patent:
August 7, 2012
Assignees:
Medarex, Inc., Amgen Inc.
Inventors:
Brian Varnum, Chris Vezina, Alison Witte, Xueming Qian, Francis Hall Martin, Haichun Huang, Gary Elliott
Abstract: Antibodies that specifically bind to toxins of C. difficile, antigen binding portions thereof, and methods of making and using the antibodies and antigen binding portions thereof are provided herein.
Type:
Grant
Filed:
July 31, 2009
Date of Patent:
August 7, 2012
Assignees:
University of Massachusetts, Medarex, Inc.
Inventors:
Donna M. Ambrosino, Gregory J. Babcock, Teresa Broering, Robert Graziano, Hector Javier Hernandez, Israel Lowy, Robert Mandell, Deborah Molrine, William D. Thomas, Jr., Hui-Fen Zhang
Abstract: The invention provides transgene constructs for expressing chimeric antibodies, and transgenic non-human host animals carrying such constructs, wherein the chimeric antibodies comprise human variable regions and constant regions of the non-human transgenic host animal. The presence of immunoglobulin constant regions of the host animal allows for generation of improved antibodies in such transgenic host animals. Subsequently, the chimeric antibodies can be readily converted to fully human antibodies using recombinant DNA techniques. Thus, the invention provides compositions and methods for generating human antibodies in which chimeric antibodies raised in vivo in transgenic mice are used as intermediates and then converted to fully human antibodies in vitro.
Type:
Grant
Filed:
February 17, 2011
Date of Patent:
July 31, 2012
Assignee:
Medarex, Inc.
Inventors:
Dawn M. Tanamachi, Peter Brams, Amelia Black
Abstract: The present invention relates to binding compounds specific for BTLA and uses thereof. More specifically, the invention relates to fully human antibodies that recognize human BTLA and modulate its activity in cancer, inflammatory, and autoimmune disorders.
Type:
Application
Filed:
July 26, 2010
Publication date:
July 19, 2012
Applicants:
N.V. ORGANON, MEDAREX, INC.
Inventors:
Jennifer Marie Mataraza, Andrea Van Elsas, Alan J. Korman, Edward L. Halk, Kent B. Thudium, Mark Selby, Timothy W. Sproul, Heidi N. Leblanc
Abstract: The present invention provides isolated monoclonal antibodies, particularly human monoclonal antibodies, that specifically bind to PTK7 with high affinity. Nucleic acid molecules encoding the antibodies of the invention, expression vectors, host cells and methods for expressing the antibodies of the invention are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the invention are also provided. The invention also provides methods for detecting PTK7, as well as methods for treating various diseases, including cancer and infectious diseases, using anti-PTK7 antibodies.
Type:
Grant
Filed:
December 8, 2006
Date of Patent:
July 17, 2012
Assignee:
MEDAREX, Inc.
Inventors:
Jonathan Alexander Terrett, Li-Sheng Lu, Chin Pan